Pacific Excel Wealth Advisors Inc. Makes New Investment in Stryker Corporation $SYK

Pacific Excel Wealth Advisors Inc. bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,785 shares of the medical technology company’s stock, valued at approximately $562,000.

Other hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in Stryker during the fourth quarter valued at approximately $26,000. Sankala Group LLC bought a new position in Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new stake in Stryker during the third quarter worth $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG bought a new stake in Stryker during the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on SYK shares. BTIG Research reduced their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research report on Friday, July 31st. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. Finally, Truist Financial increased their price target on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Down 1.5%

Shares of SYK stock opened at $336.08 on Wednesday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock’s fifty day moving average price is $318.23 and its 200 day moving average price is $334.46. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $128.84 billion, a price-to-earnings ratio of 34.83, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 over the last 90 days. 4.60% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.